10 completed, 8 recruiting, 7 active not recruiting, 4 unknown. 35 Phase 2, 6 Phase 1, 2 Phase 3.
Follow Protons: new trials by email Literature Review of Protons trials Research Report on Protons
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2027-02-01 | 2026-11-02 |
| Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M) - Streptococcus Pneumoniae Infection | Phase 1 / Phase 2 | Recruiting | CanSino Biologics Inc. | 854 | 2026-05-24 | 2026-08-05 |
| ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg - Pulmonary Tuberculosis (TB) | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 80 | 2026-01-03 | 2026-01-23 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer Biospecimen Collection, Proton Beam Radiation Therapy, Radiology, Treatment Planning - Resectable Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Emory University | 10 | 2024-12-13 | 2026-09-16 |
| Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer Pyrotinib Maleate, Trastuzumab (H, 8mg/kg, pegylated liposomal doxorubicin hydrochloride - HER2-positive Breast Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 182 | 2024-04-30 | 2026-06-09 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide rifampicin, pyrazinamide, HRZE - Tuberculosis, Pulmonary | Phase 2 | Suspended | University Hospital, Linkoeping | 40 | 2022-11-30 | 2026-08-17 |
| Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Photon, Proton - Non-small Cell Lung Cancer Stage III, Radiotherapy Side Effect | Phase 2 | Not yet recruiting | Odense University Hospital | 182 | 2022-10-01 | 2022-09-21 |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer Leuprolide acetate, Goserelin acetate, Triptorelin acetate - Prostate Cancer | Phase 2 | Unknown | Fudan University | 160 | 2022-04-01 | 2022-03-16 |
| Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer Paclitaxel, Trastuzumab, Docetaxel - HER2-positive Breast Cancer, Adjuvant Therapy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 190 | 2022-01-31 | 2022-01-12 |
| Folfox+Irinotecan+Chemort In Esophageal Cancer FOLFOX/ nal-IRI, Paclitaxel, Carboplatin - Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2021-06-29 | 2025-11-14 |
| Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer Pyrotinib, Trastuzumab, Pertuzumab - Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2021-06-03 | 2021-06-04 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Carboplatin, Cisplatin, Computed Tomography - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 188 | 2021-04-27 | 2026-10-21 |
| A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment - Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 84 | 2020-01-06 | 2026-10-20 |
| Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma Photon, Proton, Carbon ion - Nasopharyngeal Carcinoma | Phase 2 | Completed | Shanghai Proton and Heavy Ion Center | 136 | 2019-04-29 | 2026-06-24 |
| 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging - Glioblastoma, Malignant Glioma | Phase 2 | Completed | Mayo Clinic | 43 | 2019-03-28 | 2025-07-03 |
| Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 2 | Active not recruiting | NRG Oncology | 120 | 2018-01-23 | 2026-07-28 |
Showing 20 of 35. Sign in to see all of them.
Tuberculosis, Pulmonary (6) · Carcinoma, Non-Small-Cell Lung (5) · Tuberculosis (5) · Breast Neoplasms (2) · Glioblastoma (2) · Glioma (2) · Nasopharyngeal Carcinoma (2) · Prostatic Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Astrocytoma (1) · Breast Carcinoma In Situ (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Chordoma (1) · Frailty (1)
M.D. Anderson Cancer Center (4) · Massachusetts General Hospital (4) · Mayo Clinic (3) · Loma Linda University (2) · NRG Oncology (2) · Obafemi Awolowo University Teaching Hospital (2) · CanSino Biologics Inc. (1) · Emory University (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Fudan University (1) · Global Alliance for TB Drug Development (1) · Hebei Medical University Fourth Hospital (1) · Heidelberg University (1) · National Cancer Institute (NCI) (1) · Odense University Hospital (1)
United States (19) · China (6) · Nigeria (2) · South Africa (2) · Tanzania (2) · Uganda (2) · Canada (1) · Georgia (1) · Germany (1) · Moldova (1) · Mozambique (1) · Peru (1) · Philippines (1) · Sweden (1) · Vietnam (1)
Bolanle A Omotoso, MD (2) · Olanisun O Adewole, MD (2) · Annie W Chan, MD (1) · Anthony Garcia-Prats, MD, MSc, PhD (1) · Brian J. Davis, M.D. (1) · Dan P Zandberg (1) · David A Bush, MD (1) · David A. Bush, MD (1) · David R Grosshans (1) · Dingwei Ye, Doctoral (1) · Francine Foss, M.D. (1) · Henning Willers, MD (1) · James Welsh (1) · Jennifer Wo, MD (1) · Jennifer Y. Wo, MD (1)
PMID 15508084, PMID 21264826, PMID 23433590, PMID 24663014, PMID 31996395, PMID 33051340, PMID 33096027, PMID 34749885, PMID 35273049, PMID 35315690, PMID 36808186, PMID 38768617, PMID 39571596, PMID 39651910, PMID 41616265
U10CA180868 (2), 2019 (1), P01CA021239 (1), P30CA138292 (1), P50CA127001 (1), U01AI192041 (1), U10CA180820 (1), U19CA021239 (1)